Complications associated with the use of the recombinant human bone morphogenetic proteins for posterior interbody fusions of the lumbar spine

Spine

Volumn 38, Issue 16, 2013, Pages

  Chrastil, Jesse ^a   Low, Jeffrey B ^b   Whang, Peter G ^b   Patel, Alpesh A ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

BMP; complication; heterotopic ossifi cation; HO; osteolysis; PLIF; posterior interbody fusions; posterior lumbar interbody fusion; radiculitis; recombinant human bone morphogenetic protein; rhBMP; subsidence; TLIF; transforaminal lumbar interbody fusion

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

AUTOGRAFT; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; EPIDURAL SPACE; FIXATION FAILURE; FOLLOW UP; HETEROTOPIC OSSIFICATION; HUMAN; INFORMATION RETRIEVAL; LUMBAR SPINE; MEDICAL DEVICE COMPLICATION; NEUROPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOLYSIS; POSTERIOR LUMBAR INTERBODY FUSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PSEUDARTHROSIS; RADICULITIS; REVIEW; SPINE FUSION; SURGICAL EQUIPMENT; SURGICAL TECHNIQUE; TRANSFORAMINAL LUMBAR INTERBODY FUSION;

BONE MORPHOGENETIC PROTEINS; HUMANS; LUMBAR VERTEBRAE; OSSIFICATION, HETEROTOPIC; OSTEOLYSIS; POSTOPERATIVE COMPLICATIONS; RADICULOPATHY; RECOMBINANT PROTEINS; SPINAL FUSION;

EID: 84880722847     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e3182982f8e     Document Type: Review

References (44)

1. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins: a review. Growth Factors 2004; 22: 233-41.
2. Urist MR. Bone: formation by autoinduction. Science 1965; 150: 893-9.
3. Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528-34.
4. US Food and Drug Administration. OP-1™-H010002; 2001 http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm085026.htm. Accessed November 2010.
5. US Food and Drug Administration. InFUSE™ Bone graft/LT-CAGE™ lumbar tapered fusion devices-P000058; 2002. Available at http://www.fda.gov/ MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/ recently-approveddevices/ucm083423. htm. Accessed November 2010.
6. US Food and Drug Administration. OP-1 Putty-H020008; 2004. Available at http://www.fda.gov/MedicalDevices/Productsand MedicalProcedures/ DeviceApprovalsandClearances/recently-approved devices/ucm081181.htm. Accessed November 2010.
7. US Food and Drug Administration. INFUSE/MASTERGRAFT™ Posterolateral Revision Device-H040004; 2008. Available at http://www.accessdata.fda.gov/ scripts/cdrh/cfdocs/cftopic/pma/pma.cfm? num = H040004. Accessed November 2010.
8. Ong KL, Villarraga ML, Lau E, et al. Off-label use of bone mor-phogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976) 2010; 35: 1794-800.
9. FDA Public Health Notifi cation. Life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. Available at http://www.fda.gov/Medical Devices/safety/alertsandnotices/ publichealthnotifi cations/ucm062000. htm. Accessed November 2010.
10. Medtronic. (2011, July 29). Form 10-Q.
11. Haid RW, Jr, Branch CL, Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages. Spine J 2004; 4: 527-38
12. Mummaneni PV, Pan J, Haid R W, et al. Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves. J Neurosurg Spine 2004; 1: 19-23.
13. Villavicencio A T, Burneikiene S, Nelson EL, et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2. J Neurosurg Spine 2005; 3: 436-43.
14. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976) 2007; 32: 2885-90.
15. Rihn JA, Makda J, Hong J, et al. The use of RhBMP-2 in single-level transforaminal lumbar interbody fusion: a clinical and radiographic analysis. Eur Spine J 2009; 18: 1629-36.
16. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of offlabel PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008; 8: 1011-8.
17. OP-1 FDA letter Humanitarian Device Exception. Available at http://www.fda.gov/cdrh/MDA/DOCS/h020008.html-OP-1. Accessed November 2010.
18. Chen NF, Smith ZA, Stiner E, et al. Symptomatic ectopic bone formation after off-label use of recombinant human bone mor-phogenetic protein-2 in transforaminal lumbar interbody fusion. J Neurosurg Spine 2010; 12: 40-6.
19. Patel VV, Zhao L, Wong P, et al. An in vitro and in vivo analysis of fi brin glue use to control bone morphogenetic protein diffusion and bone morphogenetic protein-stimulated bone growth. Spine J 2006; 6: 397-403
20. Rihn JA, Patel R, Makda J, et al. Complications associated with single-level transforaminal lumbar interbody fusion. Spine J 2009; 9: 623-9.
21. Lubelski D, Abdullah KG, Steinmetz MP, et al. Adverse events with the use of rhBMP-2 in thoracolumbar and lumbar spine fusions: a nine year institutional analysis. [published online ahead of print February 19, 2013] J Spinal Disord Tech 2013.
22. Potter BK, Freedman BA, Verwiebe EG, et al. Transforaminal lumbar interbody fusion: clinical and radiographic results and complications in 100 consecutive patients. J Spinal Disord Tech 2005; 18: 337-46.
23. Hackenberg L, Halm H, Bullmann V, et al. Transforaminal lumbar interbody fusion: a safe technique with satisfactory three to fi ve year results. Eur Spine J 2005; 14: 551-8.
24. Salehi SA, Tawk R, Ganju A, et al. Transforaminal lumbar interbody fusion: surgical technique and results in 24 patients. Neurosurgery 2004; 54: 368-74.
25. Muchow RD, Hsu WK, Anderson PA. Histopathologic infl am-matory response induced by recombinant bone morphogenetic protein-2 causing radiculopathy after transforaminal lumbar interbody fusion. Spine J 2010; 10: e1-6.
26. Owens K, Glassman SD, Howard JM, et al. Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion. Eur Spine J 2011; 20: 612-7.
27. Williams BJ, Smith JS, Fu KM, et al. Scoliosis Research Society Morbidity and Mortality Committee. Does bone morphogenetic protein increase the incidence of perioperative complications in spinal fusion ? A comparison of 55, 862 cases of spinal fusion with and without bone morphogenetic protein. Spine (Phila Pa 1976) 2011; 36: 1685-91.
28. Mindea SA, Shih P, Song JK. Recombinant human bone morpho-genetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review. Spine (Phila Pa 1976) 2009; 34: 1480-4.
29. Otsuka E, Notoya M, Hagiwara H. Treatment of myoblastic C2C12 cells with BMP-2 stimulates vitamin D-induced formation of osteoclasts. Calcif Tissue Int 2003; 73: 72-7.
30. Giannoudis PV, Kanakaris NK, Einhorn TA. Interaction of bone morphogenetic proteins with cells of the osteoclast lineage: review of the existing evidence. Osteoporos Int 2007; 18: 1565-81.
31. Toth JM, Boden SD, Burkus JK, et al. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 2009; 34: 539-50.
32. Seeherman HJ, Li XJ, Bouxsein ML, et al. rhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 2010; 92: 411-26.
33. Laursen M, Høy K, Hansen ES, et al. Recombinant bone mor-phogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results. Eur Spine J 1999; 8: 485-90.
34. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006; 19: 483-6.
35. Meisel HJ, Schnöring M, Hohaus C, et al. Posterior lumbar interbody fusion using rhBMP-2. Eur Spine J 2008; 17: 1735-44.
36. Vaidya R, Weir R, Sethi A, et al. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence. J Bone Joint Surg Br 2007; 89: 342-5.
37. Vaidya R, Sethi A, Bartol S, et al. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions. J Spinal Disord Tech 2008; 21: 557-62.
38. Knox JB, Dai JM, 3rd Orchowski J. Osteolysis in transforaminal lumbar interbody fusion with bone morphogenetic protein-2. Spine (Phila Pa 1976) 2011; 36: 672-6.
39. Helgeson MD, Lehman RA Jr, Patzkowski JC, et al. Adjacent vertebral body osteolysis with bone morphogenetic protein use in trans-foraminal lumbar interbody fusion. Spine J 2011; 11: 507-10.
40. Lewandrowski KU, Nanson C, Calderon R. Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of fi ve cases. Spine J 2007; 7: 609-14.
41. Balseiro S, Nottmeier EW. Vertebral osteolysis originating from sub-chondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases. Spine J 2010; 10: e6-10.
42. Crandall DG, Revella J, Patterson J, et al. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolis-thesis and degenerative disease-Part 2: BMP dosage related complications and long-term outcomes in 509 patients. Spine (Phila Pa 1976) 2013; 38: 1137-45.
43. Mannion RJ, Nowitzke AM, Wood MJ. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2-but what is the cost ? Spine J 2011; 11: 527-33.
44. Geibel PT, Boyd DL, Slabisak V. The use of recombinant human bone morphogenic protein in posterior interbody fusions of the lumbar spine: a clinical series. J Spinal Disord Tech 2009; 22: 315-20.